Quanterix Stock Forecast, Price & News

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Quanterix in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Quanterix stock.
View analyst ratings for Quanterix or view top-rated stocks.

Wall Street analysts have given Quanterix a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Quanterix wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Quanterix is scheduled to release its next quarterly earnings announcement on Tuesday, August 3rd 2021.
View our earnings forecast for Quanterix.

Quanterix Co. (NASDAQ:QTRX) issued its quarterly earnings data on Wednesday, May, 5th. The company reported ($0.29) earnings per share for the quarter, beating the consensus estimate of ($0.32) by $0.03. Quanterix had a negative net margin of 41.69% and a negative trailing twelve-month return on equity of 22.37%.
View Quanterix's earnings history.

Quanterix's stock was trading at $18.51 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, QTRX shares have increased by 143.0% and is now trading at $44.98.
View which stocks have been most impacted by COVID-19.

3 Wall Street analysts have issued twelve-month price objectives for Quanterix's shares. Their forecasts range from $40.00 to $90.00. On average, they expect Quanterix's share price to reach $66.67 in the next twelve months. This suggests a possible upside of 48.2% from the stock's current price.
View analysts' price targets for Quanterix or view top-rated stocks among Wall Street analysts.

15 employees have rated Quanterix CEO Kevin Hrusovsky on Glassdoor.com. Kevin Hrusovsky has an approval rating of 70% among Quanterix's employees.

Some companies that are related to Quanterix include Coherent (COHR), Pacific Biosciences of California (PACB), HORIBA (HRIBF), Berkeley Lights (BLI), Bionano Genomics (BNGO), Accelerate Diagnostics (AXDX), Fluidigm (FLDM), Harvard Bioscience (HBIO), EyePoint Pharmaceuticals (EYPT), Precipio (PRPO), Scientific Industries (SCND), Astrotech (ASTC), BioForce Nanosciences (BFNH), HTG Molecular Diagnostics (HTGM) and Pressure BioSciences (PBIO).
View all of QTRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Quanterix investors own include Editas Medicine (EDIT), Novavax (NVAX), Akoustis Technologies (AKTS), Advanced Micro Devices (AMD), CRISPR Therapeutics (CRSP), The Walt Disney (DIS), Illumina (ILMN), Sorrento Therapeutics (SRNE), Cisco Systems (CSCO) and Intellia Therapeutics (NTLA).

(QTRX) raised $50 million in an initial public offering on Thursday, December 7th 2017. The company issued 3,300,000 shares at $14.00-$16.00 per share. J.P. Morga and Leerink Partners served as the underwriters for the IPO and BTIG and Evercore ISI were co-managers.

Quanterix trades on the NASDAQ under the ticker symbol "QTRX."

Quanterix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Gilder Gagnon Howe & Co. LLC (8.06%), Price T Rowe Associates Inc. MD (5.79%), BlackRock Inc. (5.27%), Lord Abbett & CO. LLC (3.58%), Ameriprise Financial Inc. (2.81%) and Victory Capital Management Inc. (1.94%). Company insiders that own Quanterix stock include Amol Chaubal, David C Duffy, David R Walt, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey and Martin D Madaus.
View institutional ownership trends for Quanterix.

QTRX stock was sold by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Gilder Gagnon Howe & Co. LLC, Ameriprise Financial Inc., Royce & Associates LP, Bridger Management LLC, Ashford Capital Management Inc., Kornitzer Capital Management Inc. KS, and JPMorgan Chase & Co.. Company insiders that have sold Quanterix company stock in the last year include Amol Chaubal, David C Duffy, Dawn Mattoon, E Kevin Hrusovsky, John J Fry, Marijn E Dekkers, Mark T Roskey, and Martin D Madaus.
View insider buying and selling activity for Quanterix or view top insider-selling stocks.

QTRX stock was bought by a variety of institutional investors in the last quarter, including Lord Abbett & CO. LLC, Price T Rowe Associates Inc. MD, Victory Capital Management Inc., Baillie Gifford & Co., Goldman Sachs Group Inc., Waddell & Reed Financial Inc., Sectoral Asset Management Inc, and Bank Julius Baer & Co. Ltd Zurich.
View insider buying and selling activity for Quanterix or or view top insider-buying stocks.

Shares of QTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of QTRX stock can currently be purchased for approximately $44.98.

Quanterix has a market capitalization of $1.63 billion and generates $56.73 million in revenue each year. The company earns $-40,800,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis.

Quanterix employs 314 workers across the globe.

The official website for Quanterix is www.quanterix.com.

Quanterix is headquartered at 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821.

Quanterix's mailing address is 900 MIDDLESEX TURNPIKE, BILLERICA MA, 01821. The company can be reached via phone at 617-301-9400 or via email at [email protected]